Although the therapeutic benefits of denosumab in BC bone metastasis are debatable, it suggests that targeting the RANK/RANKL signaling pathway may influence bone PMN formation and change the outcomes of BC bone metastasis. This evidence concerns the gene TNFSF11 and breast cancer.